Study of ALN-HTT02 for Huntington's disease
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This trial tests an experimental drug called ALN-HTT02 for people with Huntington's disease. The goal is to see if it can help manage symptoms. Participants must have stage 2 or early stage 3 Huntington's disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage 2 or early stage 3 Huntington's disease
- You must not have other serious brain or nerve conditions besides Huntington's
- You must not have a weakened immune system due to infections, medical conditions, or treatments
- Your liver function tests must be within normal range
- Your kidney function must be above a certain level
- You cannot have taken any experimental drug in the past year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This first-in-human study tests whether SRP-1005, a new drug, is safe and tolerable in people with early Huntington's disease. The drug is designed to reduce levels of a harmful protein in the brain that causes Huntington's symptoms.
This trial tests a new radioactive tracer called [11C]CHDI-00491009 that may show mutant huntingtin protein in the brain using a PET scan. It aims to find out if the tracer is safe and helps see Huntington's disease changes. If you have early-stage Huntington's or are a healthy volunteer, you may be able to join.
This trial tests a new drug called SKY-0515 in people with Huntington's disease. The goal is to see if it can safely improve symptoms or slow the disease down.
This trial tests a gene therapy called SPK-10001 for people with early-stage Huntington's disease. It aims to slow the progression of symptoms by targeting the genetic cause of the disease.
This trial tests if a vitamin B3-like supplement, nicotinamide riboside, can help people with early to mid-stage Huntington's disease. You will be randomly assigned to take the supplement or a placebo to see if it slows the disease.
This Phase 2 study tests whether NAC (a supplement-like medicine) can delay symptoms in people who carry the Huntington’s disease gene expansion but do not yet have clear movement symptoms. You may be asked to take NAC and attend regular visits, scans, and blood tests to see if it changes how likely you are to develop Huntington’s disease within the next 10 years.
Hear when a new Huntington's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.